Sanofi Launches IPO Process for Its Consumer Healthcare Business in India

On March 31, according to foreign media reports, informed sources revealed that the French pharmaceutical giant Sanofi has initiated the process of spinning off its consumer health business in India into a separately listed company. Of Sanofi India's shares, approximately 60% are held by Sanofi and its wholly-owned subsidiary Hoechst Gmbh, with the remainder owned by institutional and retail investors both within and outside China.

It is reported that Sanofi is cooperating with Bank of America to spin off its consumer health care business. The key products involved in this spin-off include the antiallergic drug Allegra, pain management drug Combiflam, and vitamin Depura, among others.

In recent years, Sanofi has been continuously slimming down its operations. In June last year, Sanofi returned the global rights of PD-1 monoclonal antibody Libtayo to Regeneron for $1.1 billion (see: ); In July, Sanofi sold 17 drugs to Neuraxpharm for an undisclosed amount, including two product portfolios for central nervous system (CNS) diseases, pain, and vascular diseases. In 2021, Sanofi also sold 16 consumer healthcare products to Germany’s Stada Arzneimittel, covering cold and flu medications, skincare, and dietary supplement brands.

At the same time, Sanofi's investment in its innovative product pipeline is continuously increasing. Half a month ago, Sanofi just reached an agreement with Provention Bio to acquire the latter for nearly 2.9 billion US dollars, obtaining Teplizumab, a marketed drug for Type 1 Diabetes (T1D). (See: )

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reproduce it, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank you for your companionship. Looking forward to your feedback.

Scan the QR code to provide valuable suggestions